Wagner, A D <br/><br/>
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Jan 2007 
 - 82-87 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0923-7534 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdl340  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Deoxycytidine--administration & dosage<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Infusions, Intravenous<br/>Male<br/>Middle Aged<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Pancreatic Neoplasms--drug therapy<br/>Quality of Life<br/>Survival Rate<br/>Time Factors<br/>Treatment Outcome<br/>Gemcitabine